Genentech's ITOVEBI NDA219249 Submission Receives AP Status
The FDA has granted an Approval Pending (AP) status for Genentech's supplemental NDA for ITOVEBI (Inavolisib).
Asset / Drug
Drug and asset intelligence for ITOVEBI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
PI3K Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.